Dominance of the α_1B-Adrenergic Receptor and its Subcellular Localization in Human and TRAMP Prostate Cancer Cell Lines

REFERENCES

• Piascik M T, Perez D M. α1-Adrenergic receptors: New insights and directions. J Pharmacol Exp Ther 2001; 298: 403–410
   PubMed Web of Science ®Google Scholar
• Price D T, Schwin D A, Lomasney J W, Allen L F, Caron M G, Lefkowitz R J. Identification quantification and localization of mRNA for three distinct α1 adrenoceptor subtypes in human prostate. J Urol 1993; 150: 546–551
   PubMed Web of Science ®Google Scholar
• Chapple C R, Burt R P, Anderson P O, Greengrass P, Wyllie M, Marshall I. α1-Adrenoceptor subtype in the human prostate. Br J Urol 1994; 74: 585–589
   PubMedGoogle Scholar
• Forray C, Bard J A, Wetzel J M, Chiu G, Shapiro E, Tang R, Lepor H, Hartig P R, Weinshank R L, Branhek T A, Gluchowski C. The α1-AR that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human α1 a subtype. Mol Pharmacol 1994; 45: 703–708
   PubMed Web of Science ®Google Scholar
• Wingo P A, Tong T N, Bolden S. Cancer statistics. CA Cancer J Clin 1997; 47: 5–27
   PubMed Web of Science ®Google Scholar
• Woolf S H. Screening for the prostate cancer with prostate-specific antigen. An examination of evidence. N Engl J Med 1995; 333: 1401–1405
   PubMed Web of Science ®Google Scholar
• Isaacs J T. The role of androgens in prostatic cancer. Vitam Horm 1994; 49: 433–502
   PubMed Web of Science ®Google Scholar
• Abate-Shen C, Shen M M. Molecular genetics of prostate cancer. Genes Dev 2000; 14: 2410–2434
   PubMed Web of Science ®Google Scholar
• Lepor H, Tang R, Kobayashi S, Shapiro E, Forray C, Wetzel J M, Gluchowski C. Localization of the α 1 A-adrenoceptor in the human prostate. J Urol 1995; 154: 2096–2099
   PubMed Web of Science ®Google Scholar
• Kyprianou N, Litvak J, Alexander R B, Borkowski A, Jacobs S C. Induction of prostate apoptosis by doxazosin. J Urol 1998; 159: 1810–1815
   PubMedGoogle Scholar
• Kyprianou N, Lepor H, Wyllie M G. Prostatic adrenoceptors and uroselectivity. Prostate 1997; 3: 202–20
   Google Scholar
• Caine M. α1-Adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol Clin N Am 1990; 17: 641–650
   PubMed Web of Science ®Google Scholar
• Walden P D, Durkin M M, Lepor H, Wetzel J M, Gluchowski C, Gustaffson E L. Localization of mRNA and receptor binding sites for the α1a-adrenoceptor subtype in the rat, monkey, and human urinary bladder and prostate. J Urol 1997; 157: 1032–1038
   PubMed Web of Science ®Google Scholar
• Chon J, Borkowski A, Partin A W, Isaacs J T, Jacobs S C, Kyprianou N. α1-Adrenoceptor antagonists, prazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patient with benign prostatic hyperplasia. J Urol 1999; 161: 2002–2007
   PubMed Web of Science ®Google Scholar
• Foster B A, Gingrich J R, Kwon E D, Madias C, Greenberg N M. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997; 57: 3325–30
   PubMed Web of Science ®Google Scholar
• Awaji T, Hirasawa A, Kataoka M, Shinoura H, Nakayama Y, Sugawara T, Izumi S, Tsujimoto G. Real-time optical monitoring of ligand-mediated internalization of α1b-adrenoceptor with green fluorescent protein. Mol Endocrinol 1998; 12: 1099–1111
   Google Scholar
• Perez D M, DeYoung M B, Graham R M. Coupling of expressed α1B- and α1D-adrenergic receptors to multiple signaling pathways is both G-protein and cell-type specific. Mol Pharmacol 1993; 44: 784–795
   PubMed Web of Science ®Google Scholar
• Gupta A, Devi L A. The use of receptor-specific antibodies to study G-protein-coupled receptors. Mt Sinai J Med 2006; 73: 673–681
   Google Scholar
• Vicentic A, Robeva A, Rogge G, Uberti M, Minneman K P. Biochemistry and pharmacology of epitope-tagged α1-adrenergic receptor subtypes. J Pharmacol Exp Ther 2002; 302: 58–65
   Google Scholar
• Chalothorn D, McCune D F, Edelmann S E, Garcia-Cazarin M L, Tsujimoto G, Piascik M T. Differences in the cellular localization and agonist-mediated internalization properties of the α1-adrenoceptor subtypes. Mol Pharmacol 2002; 61: 1008–1066
   PubMed Web of Science ®Google Scholar
• Fonseca M I, Button D C, Brown R D. Agonist regulation of α1B-Adrenergic receptor subcellular distribution and function. J Biol Chem 1995; 270: 8902–8909
   Google Scholar
• Sugawara T, Hirasawa A, Hashimoto K, Tsujimoto G. Differences in the subcellular localization of α 1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin. Life Sci 2002; 70: 2113–2224
   Google Scholar
• Gether U, Ballesteros J A, Seifert R, Sanders-Bush E, Weinstein H, Kobilka B K. Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem 1997; 272: 2587–2590
   PubMed Web of Science ®Google Scholar
• Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365: 649–51
   PubMed Web of Science ®Google Scholar
• Perry S J., Lefkowitz R J. Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol 2002; 12: 130–138
   PubMed Web of Science ®Google Scholar
• Chen Z, Hague C, Hall R A, Minneman K P. Syntrophins regulate α1D-adrenergic receptors through a PDZ domain-mediated interaction. J Biol Chem 2006; 281: 12414–12420
   PubMed Web of Science ®Google Scholar
• Thebault S, Roudbaraki M, Sydorenko V, Shuba Y, Lemonnier L, Slomianny C, Dewailly E, Bonnal J L, Mauroy B, Skryma R, Prevarskaya N. α1-Adrenergic receptors activate Ca (2+)-permeable cationic channels in prostate cancer epithelial cells. J Clin Invest 2003; 111: 1691–1701
   PubMedGoogle Scholar
• Quaglia W, Santoni G, Pigini M, Piergentili A, Gentili F, Buccioni M, Mosca M, Lucciarini R, Amantini C, Nabissi M I, Ballarini P, Poggesi E, Leonardi A, Giannella M. Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) 2-[2-(4 chlorobenzyloxy) phenoxy]ethyl-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of α1D- and α1B-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation. J Med Chem 2005; 48: 7750–7763
   Google Scholar
• Esbenshade T A, Han C, Murphy T J, Minneman K P. Comparison of α1-adrenergic receptor subtypes and signal transduction in SK-N-MC and NB41A3 neuronal cell lines. Mol Pharmacol 1993; 44: 76–86
   Google Scholar
• Han C, Esbenshade T A, Minneman K P. Subtypes of alpha 1-adrenoceptors in DDT1 MF-2 and BC3 H-1 clonal cell lines. Eur J Pharmacol 1992; 226: 141–148
   Google Scholar
• Gonzalez-Cabrera P J, Ting Shi, Yun J, McCune D F, Rorabaugh B, Perez D M. Differential regulation of the cell cycle by α1-adrenergic receptor subtypes. Endocrinology 2004; 145: 5157–5167
   PubMed Web of Science ®Google Scholar
• Price D T, Rudner X, Michelotti G A, Schwinn D A. Immortalization of a human prostate stromal cell line using a recombinant retroviral approach. J Urol 2000; 164: 2145–2150
   Google Scholar
• Xu K, Wang X, Ling M, Wong Y. Growth inhibiting effects of terazosin on androgen-independent prostate cancer cell lines. Chin Med J (Engl) 2003; 116: 1673–1677
   Google Scholar
• Kyprianou N, Chon J, Benning C M. Effects of α1-adrenoceptor (α1-AR) antagonists on cell proliferation and apoptosis in the prostate: Therapeutic implications in prostatic disease. Prostate Suppl 2000; 9: 42–46
   PubMedGoogle Scholar
• Benning C M, Kyprianou N. Quinazoline-derived α1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an α1-adrenoceptor-independent action. Cancer Res 2002; 62: 597–602
   PubMed Web of Science ®Google Scholar